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It is very desirable to design dual-mode nanocomposites for diagnostic applications via 
flexible strategies. Herein, we proposed to synthesize one type of multifunctional magnetic 
resonance (MR)/optic nanocomposites based on manganese ferrite magnetic nanoparticles 
(MFNPs) modified by fluorescent podoplanin (PDPN) antibodies. MFNPs were 
synthesized using a thermal decomposition method and were modified by the fluorescent 
PDPN antibodies on their surfaces. The fluorescent PDPN antibody-conjugated MFNPs 
enabled strong MR imaging and fluorescence imaging due to the antibodies that targeted 
brain tumors. These results demonstrate that MR/optic nanocomposites have potential as 
precision diagnostic systems for brain cancer. 
 
(Received May 22, 2020; Accepted August 10, 2020) 
 
Keywords: MRI, Optical imaging, Brain cancer, Glioblastoma multiforme, Podoplanin,  
         GSC11  
 
 
1. Introduction  
 
Medical imaging technologies, such as magnetic resonance imaging (MRI), X-ray 
computed tomography (CT), ultrasound imaging, and optical imaging, have been widely used for 
disease diagnosis.1-5 However, it is difficult for any single imaging modality to provide sufficient 
information for a precise diagnosis. A promising strategy is to develop multimodal contrast agents 
for different imaging modalities, such as MRI/CT, CT/fluorescence imaging, and MRI/ultrasound 
imaging, which can combine their individual advantages in disease diagnosis. 6-8 Specifically, MRI 
has emerged as a key tool in the diagnosis of cancer, since it has advantages over noninvasive 
anatomical imaging due to its high resolution, high contrast, and ability to provide three-
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dimensional information in real time, much more so than nuclear medicine (positron electron 
tomography and single-photon emission computed tomography).
9,10
 In addition, molecular MRI is 
able to detect simultaneously the metabolism of cells and tissues, physiological and structural 
information, and biological processes occurring in deep tissues.11-14 In particular, the use of near-
infrared (NIR) light (700 ∼ 1,000 nm) for optical imaging can penetrate several centimeters into 
tissue, because hemoglobin and water, the primary absorbers of visible and infrared light, 
experience their lowest absorptions in the NIR region. Thus, NIR imaging offers a potentially non-
invasive and real-time characterization of diseased tissues using optical imaging probes including 
quantum dots and fluorescent-dye-doped nanoparticles.15-19 
Glioblastoma multiforme is a lethal intracranial cancer, which exhibits a relentless 
malignant progression that is highly resistant to conventional combination therapies such as 
traditional radiation and chemotherapy agents.20 Therefore, the early detection of glioblastoma is 
very crucial for effective treatment. Traditionally, as MRI plays a major role in the imaging of 
neovascularization in the tumor’s micro-environment, it is crucial in predicting the metastasis of 
the cancer.21 However, the weak point of MRI is sensitivity; the use of optical imaging enables us 
to increase the sensitivity and compensate for the disadvantages of MRI.22 In particular, it can 
increase the contrast and sensitivity for new blood vessels, which can cause great synergy.23 
Herein, we proposed to synthesize one magnetic resonance (MR)/optic dual-mode 
nanocomposites based on manganese ferrite magnetic nanoparticles (MFNPs) modified with 
fluorescent podoplanin antibodies. The fluorescent podoplanin antibody-conjugated MFNPs 
enabled strong MRI and fluorescence imaging due to the antibodies targeted to the brain tumor. 
These results demonstrate that MR/optic nanocomposites have potential as precision diagnostic 




Scheme 1. Schematic illustration of PDPN-targetable opto-magnetic nanoprobes for 
 molecular imaging of brain cancer. GBM, glioblastoma multiform 
 
 
2. Experiment details 
 
2.1. Materials 
Polysorbate 80, ethylenediamine, 1,4-dioxane (99.8%), 4-dimethylaminopyridine, 
triethylamine, and succinic anhydride (SA) were purchased from Sigma Aldrich Chemical Co. 
Phosphate buffered saline (PBS: 10 mM, pH 7.4) and Dulbecco’s modified Eagle’s medium 
(DMEM) were purchased from Corning Incorporated, 1x B27 supplement was purchased from 
Invitrogen, and basic fibroblast growth factor (bFGF: 20 ng/ml) and epidermal growth factor (EGF: 
20 ng/ml) were purchased from Sigma. Fetal bovine serum (FBS) and antibiotic-antimycotic 
solution were purchased from Gibco. GSC11 cell lines (American Type Culture Collection) were 
grown in medium containing 10% fetal bovine serum and 1% antibiotic-antimycotic at 37 °C in a 
humidified 5% CO2 atmosphere. Ultrapure deionized water was used for all of the syntheses. 
 
2.2. Synthesis of magnetic nanoparticles 
To synthesize monodispersed magnetic nanoparticles (MNPs), 2 mmol of iron (III) 
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acetylacetonate, 1 mmol of manganese(II) acetylacetonate, 10 mmol of 1,2-hexadecanediol, 6 
mmol of dodecanoic acid, and 6 mmol of dodecylamine were dissolved in 20 mL of benzyl ether 
under an ambient nitrogen atmosphere. The mixture was then pre-heated to 200 °C for 2 hours and 
refluxed at 300 °C for 30 minutes. After the reactants were cooled to room temperature, the 
products were purified with an excess of pure ethanol. Approximately 11 nm of MFNPs were 
synthesized using the seed-mediated growth method.24,25,26 
 
2.3. Modification of polysorbate 80 
To prepare charged MNPs, the hydroxyl groups of the NPs were modified with carboxyl 
groups. For the preparation of carboxylated polysorbate 80 (anionic polysorbate, AP) using SA, 
first, 5 mmol NP and 20 mmol SA were dissolved in a flask containing 100 ml of 1,4-dioxane, and 
the reactant solution was stirred for 1 h. Subsequently, 20 mmol dimethylaminopyridine and 
triethylamine were added to the reactor at room temperature. After further reaction for 24 h, the 
unwanted solvent was rapidly eliminated using a rotary evaporator. The obtained transparent gel-
type product was then dissolved in 10 ml of deionized water and dialyzed against an excess 
aqueous phase for at least seven days. The purified product was freeze-dried and stored under 
vacuum for later use. The characteristic bands of modified polysorbate 80 were confirmed by 
Fourier-transform infrared spectroscopy. 
 
2.4. Preparation of PDPN-targetable opto-magnetic nanoprobes 
Three types of carboxylated MFNPs were prepared by the nanoemulsion method. The 
MFNPs (30 mg) were dissolved in 4 ml of hexane (as the organic phase), and the organic phase 
was then mixed with 20 ml of deionized water (as the aqueous phase) containing 100 mg 
carboxylated polysorbate 80. After mutual saturation of the organic and aqueous phases, the 
emulsion was ultra-sonicated in an ice-cooled bath for 15 min at 190 W. Next, the organic solvent 
was evaporated overnight at room temperature, and the products were purified by centrifugal 
filtration (Centriprep YM-3, 3,000 Da, Amicon) with two cycles at 3,000 rpm for 1 h. PerCP-
eFluor® 710-podoplanin-coated MFNPs were fabricated by 1-ethyl-3-(-3-dimethylaminopropyl) 
carbodiimide hydrochloride (EDC)-N-hydroxysuccinimide (NHS) chemistry. First, the pH of the 
aminated MFNP solution was adjusted to a neutral condition by the addition of 0.1 N HCl solution. 
Then, PerCP-eFluor® 710-podoplanin was dissolved in the 40 ml of de-ionized water followed by 
the addition of EDC and sulfo-NHS.  
 
2.5. Biocompatiblility test for PDPN-targetable opto-magnetic nanocomposites 
The cytotoxic effects of PDPN-targetable opto-magnetic nanocomposites in GSC11 were 
evaluated by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay. GSC11 
cells were maintained in DMEM with 10% FBS and 1% antibiotics at 37 °C in a humidified 
atmosphere with 5% CO2. GSC11 cells (1.0 × 10
4 cells/well) were seeded into a 96-well plate at 
37 °C overnight, and the cells were then incubated with various concentrations of PDPN-targetable 
opto-magnetic nanocomposites for 4 h. The cells were washed with 100 µl of PBS (pH 7.4, 1 mM), 
and 100 µl of phenol red-free DMEM were added. Subsequently, the cells were treated with MTT 
assay solution according to the manufacturer’s instructions. Cell viability was evaluated using a 
microplate reader (Synergy H4 hybrid reader, BioTek) at an absorbance wavelength of 575 nm 
(reference wavelength of 650 nm).  
 
2.6. Prussian blue staining 
GSC11 cells (1.0 × 106 cells/well) were seeded into 6-well plates and incubated at 37 °C. 
Various prepared concentrations of PDPN opto-magnetic nanocomposites were mixed with 
DMEM, and these mixtures were added to the cells. After incubation for 4 h at 37 °C, the cells 
were washed with PBS and fixed with 4% paraformaldehyde. The working solution was prepared 
by mixing 10% potassium ferrocyanide and 20% HCl in equal amounts. The working solution was 
added to the cells and incubated for 30 min at room temperature. The cells were then washed with 
PBS and stained with nuclear fast red solution for 30 min at room temperature. The cells were 




2.7. Animal model and experimental procedure 
All animal experiments were conducted with the approval of the Association for 
Assessment and Accreditation of Laboratory Animal Care International. Female BALB/C-Slc nude 
mice at 7-8 weeks of age were anesthetized by intraperitoneal injection of a Zoletil/Rompun 
mixture and injected with 200 ml containing 1.0 × 107 GSC11 cells suspended in saline into the 
brain. After cancer cell implantation, MRI was performed between two and three weeks. After 
MRI, organ MRI was also performed. In addition, the extracted tumor tissues from the tumor-
bearing brains treated with opto-magnetic nanoparticles were sectioned and stained using Prussian 
blue. All stained tissue sections were analyzed using a virtual microscope (Olympus BX51, Japan) 
and OlyVIA software (Olympus). 
 
2.8. Magnetic resonance imaging  
We performed solution and in vitro MRI experiments with a 3T clinical MRI instrument 
with a micro-47 surface coil (Intera, Philips Medical Systems, Best, The Netherlands). The R2 (T2 
relaxation rate, 1/T2, s−1) was measured using the Carr-Purcell-Meiboom-Gill sequence at room 
temperature with the following parameters: TR = 10 s, 32 echoes with 12 ms even echo space, 
number of acquisitions = 1, point resolution of 156×156 m, and section thickness of 0.6 mm. 
Additionally, in vivo MRI experiments were performed with a 3T Siemens clinical MRI 
instrument using a human wrist coil with a T2 TSE sequence (TR: 4,000 ms, TE: 114 ms, slice 
thickness: 1.0 mm, FOV read: 180 mm). 
 
2.9. Optical imaging  
GSC11 brain tumor-bearing mice were imaged by positioning each mouse on an animal 
plate, heated to 37 °C, in the IVIS spectrum system (Caliper Life Science, Hopkinton, MA, USA) 
per the manufacturer’s instructions. Excitation and emission spots were raster-scanned over the 
selected region of interest (ROI) to generate emission wavelength scans; the wavelengths of 
fluorescence were 488 nm and 520 nm, respectively, for the ex vivo samples. All data, including 
whole body and two-dimensional slice images, were calculated using the ROI function of the 
Analysis Workstation software. 
 
 
3. Results and discussion 
 
3.1. Cell viability testing of PDPN opto-magnetic nanocomposites 
The MTT assay was performed, in which yellow tetrazolium salt is reduced to purple 
formazan crystals in metabolically active cells. The relative percentage of cell viability was 
determined as the ratio of formazan intensity in viable cells that were treated with PDPN opto-
magnetic nanoprobes to the intensity in the cells. As shown in Fig. 1, the in vitro cytotoxicity 
measured by MTT assay showed that the viability of GSC11 cells was about 80% at a 
concentration of 3.98 µg Fe + Mn/ml.  
 
Concentration (g/mL)





















Fig. 1. In vitro cytotoxicity test for PDPN opto-magnetic nanocomposites for  
in vivo dual image analysis. 
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3.2. In vivo dual image analysis  
In Fig. 2, MR signal enhancement was identified after injection with PDPN-based opto-
magnetic nanoparticles. Initially, the center of the tumor darkened instantly, and enhanced MRI 
signal intensity at the surrounding vessels was simultaneously observed. In T2 TSE MR images, 
clear anatomic details were observed, and there were no artifacts due to a difference in 
susceptibility. The anatomic details were also clear in the optical images observed via fluorescence 





Fig. 2. In vivo MR and optical imaging using PDPN opto-magnetic nanocomposites: 
(A) MR images, (B) optical images, and (C) quantitative graphs of A and B. 
   
 
3.3. Histological analysis  
In Fig. 3(A), we confirmed the tumor’s morphology using hematoxylin and eosin staining. 
This demonstrated the property of the tumor cells, which had more and larger nuclei. Therefore, 
we noticed that each of the cancer cells could be well identified through the hematoxylin (nuclei: 
blue) and eosin Y (cytoplasm: pink) staining. In Fig. 3(B), the iron contents (black arrows) of the 
accumulated opto-magnetic nanoprobes in the tumors were observed by Prussian blue staining. In 
Fig. 3(C), the podoplanin-targeted fluorescence in the tumor was observed by confocal microscope. 
Consequently, we confirmed that our developed opto-magnetic nanoprobes for dual imaging have 












The potential application of a dual imaging probe for MR and optical imaging in 
glioblastoma multiform diagnosis using a GSC11 brain cancer model was investigated based on a 
mouse brain cancer model. Our results suggested that the dual probe for MR and optical probe 
imaging was able to improve the diagnostic application for glioma. Such findings might have a 
great impact on clinical studies for the early detection of brain cancer. In addition, this method 
makes it possible to use a variety of imaging devices, thus ameliorating the disadvantages of each 
imaging device. Further investigations are warranted to evaluate the potential of this technique in 





MRI: magnetic resonance imaging; MFNPs: manganese ferrite magnetic nanoparticles; 
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